Trulicity Adolescent (12-17) Caregiver Administration Guidance

Why Caregivers Are Central to Adolescent Dulaglutide Therapy

Adolescents aged 12-17 with type 2 diabetes often rely on a parent or guardian to prepare, administer, or supervise their weekly Trulicity injection. The FDA approved dulaglutide for pediatric patients aged 10 and older in June 2020, based on the AWARD-PEDS trial (NCT02963766), which enrolled 154 pediatric patients and demonstrated statistically significant HbA1c reductions at 26 weeks [1]. Because adolescents vary widely in their readiness for self-injection, the prescribing team must assess each patient individually and document who will perform the injection at home [2].

What the FDA Approval Covers

The FDA label for Trulicity specifies the starting dose as 0.75 mg once weekly for pediatric patients, with an option to escalate to 1.5 mg once weekly after at least 4 weeks if additional glycemic control is needed [3]. The label does not restrict caregiver administration. A caregiver may perform the injection provided they have received in-office training and can demonstrate competency with the autoinjector device.

How Caregiver Involvement Affects Adherence

A 2022 analysis published in Diabetes Care found that adolescents with type 2 diabetes whose caregivers were actively involved in medication administration had significantly higher medication possession ratios than those managing injections alone [4]. Weekly injectable regimens, as opposed to daily oral agents, may reduce caregiver burden compared to multiple daily insulin injections, though GI side effects require active monitoring in the first 4-8 weeks of therapy [5].

Understanding the Trulicity Single-Dose Pen

Trulicity is supplied as a single-use, pre-filled pen autoinjector. No mixing, drawing, or priming is required. The needle is never visible before, during, or after injection, which reduces needle anxiety for many adolescent patients and their caregivers [3].

Pen Components Caregivers Must Recognize

• The clear base contains the medication window. Before each injection, confirm the solution is clear, colorless to slightly yellow, and free of particles.
• The gray plunger is visible through the window. It moves during injection.
• The green injection button is pressed to deliver the dose. One click indicates the injection has started; a second click signals completion.
• The green cap covers the needle and must be removed only immediately before injection.

The FDA-approved Medication Guide and Instructions for Use that accompany each pen provide device-specific diagrams [3]. Caregivers should read these in full at dispensing and keep them accessible.

Confirming Pen Integrity Before Each Use

Check the expiration date printed on the label. Inspect the medication window. Discard the pen if the solution is cloudy, discolored, or contains visible particles [3]. Never use a pen that has been frozen, even if it later thaws and appears normal. Freezing can degrade the peptide structure and reduce efficacy without any visible sign of damage [6].

Step-by-Step Caregiver Injection Procedure

The following sequence reflects the FDA-approved Instructions for Use and standard subcutaneous injection technique as described in ADA clinical practice resources [2] [3].

Step 1: Preparation (5 Minutes Before Injection)

1. Remove the pen from the refrigerator 30 minutes before the scheduled injection. Cold medication increases injection-site discomfort.
2. Wash hands thoroughly with soap and water for at least 20 seconds.
3. Gather supplies: alcohol swab, pen, and a sharps disposal container.
4. Confirm the scheduled injection day. Trulicity is administered on the same day each week [3].

Step 2: Choosing and Preparing the Injection Site

Approved sites are the abdomen (at least 2 inches from the navel), the front of the upper thigh, or the outer upper arm. Rotate among these sites each week to reduce lipodystrophy risk [3].

Wipe the selected site with an alcohol swab and allow it to air-dry completely. Injecting through wet skin increases the risk of localized skin reaction [7].

Step 3: Delivering the Injection

1. Pull the green cap straight off. Do not twist. Do not recap after removal.
2. Press the flat end of the pen firmly against the skin at a 90-degree angle.
3. Press and hold the green button until the first click is heard.
4. Continue holding firmly against the skin until the second click is heard (approximately 5-10 seconds). The gray plunger will have moved to the end of the window, confirming full dose delivery.
5. Remove the pen from the skin. The needle retracts automatically.
6. Do not rub the injection site. Apply gentle pressure with a dry cotton ball if there is minor bleeding [3].

Step 4: Safe Disposal

Place the used pen immediately into an FDA-cleared sharps container. Do not place in household trash or recycle bins. When the container is three-quarters full, seal it and follow your municipality's disposal instructions [8].

Storage Requirements for Caregivers

Proper storage maintains dulaglutide's peptide integrity. Errors here are a common and preventable source of treatment failure [6].

Refrigerated Storage

Store pens in the original carton in the refrigerator between 36 °F and 46 °F (2 °C and 8 °C). Keep pens away from the freezer compartment and away from the refrigerator walls, where temperatures can drop below freezing [3].

Room-Temperature Storage

If refrigeration is unavailable (travel, school trips, sports events), pens may be stored at room temperature up to 77 °F (25 °C) for a maximum of 14 days. After 14 days at room temperature, the pen must be discarded even if medication remains [3].

Caregivers should mark the date a pen is removed from refrigeration on the pen label or on a phone calendar reminder.

Travel Considerations for Adolescents

A small insulated medication pouch with a gel ice pack (not direct ice contact) keeps the pen within range during travel. The TSA permits injectable medications in carry-on luggage with appropriate prescription labeling [9]. Caregivers should carry a copy of the prescription and a letter from the prescriber when traveling internationally.

Managing Missed Doses

Missed doses are a real-world problem in adolescent chronic disease management. A large retrospective review of GLP-1 receptor agonist adherence in adolescents found that roughly 28% of weekly injectable doses were missed in the first 6 months of therapy, most often due to schedule disruption rather than intentional non-adherence [4].

The 3-Day Rule

If a dose is missed and at least 3 days remain before the next scheduled dose, administer the missed dose as soon as remembered. If fewer than 3 days remain before the next scheduled weekly dose, skip the missed dose entirely and resume the normal weekly schedule [3].

Do not double-dose to compensate. Doubling increases GI side-effect severity without improving glycemic outcomes.

Resetting the Injection Day

If the caregiver needs to permanently shift the weekly injection day (for example, to match a school schedule), the new day may be chosen as long as the prior dose was given at least 3 days earlier [3]. Document the change in the patient's log and notify the prescribing team at the next visit.

Recognizing and Managing Side Effects in Adolescents

The AWARD-PEDS trial showed that GI adverse events (nausea, vomiting, diarrhea, abdominal pain) were the most common side effects in the pediatric cohort, occurring in approximately 30-40% of participants during the first 4-8 weeks of therapy [1]. Most resolved without discontinuation.

Early GI Side Effects

Nausea peaks during weeks 1-4 and typically diminishes by week 8. Caregivers can reduce severity by:

• Serving smaller, lower-fat meals on injection day and the following day.
• Avoiding high-fat, high-sugar foods in the 2 hours after injection.
• Ensuring the adolescent remains well-hydrated, especially if vomiting occurs.

If vomiting is severe enough to affect oral hydration for more than 24 hours, the prescribing team should be contacted. Persistent vomiting can mask hypoglycemia signs and lead to dangerous dehydration in adolescents [10].

Hypoglycemia Risk

When used as monotherapy or with metformin, the hypoglycemia risk from dulaglutide alone is low, as the drug's insulin-secretory effect is glucose-dependent [3]. However, if the adolescent is also using insulin or a sulfonylurea, hypoglycemia risk increases. Caregivers should know the adolescent's target blood glucose range, keep fast-acting glucose (15 g) accessible, and review the "15-15 rule" with the clinical team [2].

Signs Requiring Immediate Medical Attention

Contact emergency services or go to the nearest emergency department if the adolescent develops:

• Severe, persistent abdominal pain radiating to the back (possible pancreatitis)
• A lump or pain in the neck with difficulty swallowing (possible thyroid tumor)
• Severe allergic reaction: swelling of the face, lips, or throat; difficulty breathing; rapid heartbeat [3]

The FDA label carries a boxed warning for the risk of thyroid C-cell tumors, based on rodent studies. While the relevance to humans is not confirmed, dulaglutide is contraindicated in any patient with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 [3].

Monitoring Plan for Caregivers and the Clinical Team

The ADA Standards of Medical Care in Diabetes (Section 14, Children and Adolescents) recommends HbA1c measurement every 3 months for pediatric patients with type 2 diabetes on pharmacotherapy, with individual targets generally set at less than 7% for most adolescents who can achieve this without significant hypoglycemia [2].

What Caregivers Should Track Between Visits

The following four-domain tracking framework may help caregivers organize their weekly observations before clinic appointments:

| Domain | What to Log | Frequency | |---|---|---| | Injection site | Location used, any redness, swelling, or bruising lasting more than 48 hours | Each injection | | GI symptoms | Nausea, vomiting, diarrhea rated 0-10 | Daily for first 8 weeks | | Blood glucose | Fasting and 2-hour post-meal values if self-monitoring is prescribed | Per clinical team guidance | | Missed doses | Date, reason, action taken | Any missed week |

Bringing this log to each clinic visit gives the prescribing team concrete data to assess tolerability, adjust dosing, and address adherence barriers before they become long-term patterns.

Laboratory Monitoring Beyond HbA1c

The clinical team will typically monitor:

• Renal function (SCr, eGFR) at baseline and annually, given dulaglutide's renal effects at higher doses [3]
• Liver function if the adolescent has obesity-related hepatic steatosis
• Lipid panel annually per ADA pediatric guidelines [2]

School and Social Considerations for Adolescent Caregivers

Managing a weekly injectable medication during adolescence involves navigating school policies, peer dynamics, and the adolescent's own privacy preferences. These practical factors affect adherence as much as clinical ones.

Coordinating with the School Nurse

Most U.S. Public schools require a completed medication authorization form and a copy of the prescription for any injectable medication stored on campus. Caregivers should contact the school nurse before the first injection day at school and provide a spare pen, sharps container, and written emergency instructions. The pen can be stored in the nurse's office refrigerator [9].

Adolescent Privacy and Self-Administration Readiness

The ADA acknowledges that adolescents with chronic conditions benefit from a gradual shift toward self-management, with caregiver involvement tapering as the adolescent demonstrates competency [2]. At each visit, the clinical team should formally assess whether the adolescent is ready to self-inject with caregiver supervision, which typically occurs between ages 14 and 16 for most patients in clinical practice, though individual readiness varies considerably.

Caregivers should avoid administering the injection in social settings unless absolutely necessary. Giving adolescents agency over the injection site and the day of the week, within the constraints of the weekly schedule, increases ownership and reduces resistance.

When to Contact the Prescribing Team

Caregivers should not wait for scheduled appointments to report the following:

• Injection-site reactions that do not resolve within 3-5 days
• Nausea or vomiting persisting beyond 4 weeks on the starting dose
• Two or more missed doses in a month due to the adolescent refusing injection
• Any new neck mass, persistent hoarseness, or difficulty swallowing
• Blood glucose readings consistently above 250 mg/dL despite adherent dosing
• Any confirmed hypoglycemic episode requiring third-party assistance [3] [10]

Early communication allows the team to adjust the escalation timeline, change the injection day, or add behavioral support before problems compound.